Idiopathic pulmonary fibrosis is marked by tissue scarring that hinders the functioning of the lung. Credit: daniiD/Shutterstock.

Rein Therapeutics has announced a partnership to integrate UK-based core imaging laboratory Qureight’s deep-learning platform into the upcoming Phase II trial of multi-pathway Caveolin-1-related peptide, LTI-03, for idiopathic pulmonary fibrosis (IPF) treatment.

The platform will be leveraged for the analysis of lung imaging data and to detect correlations between the volumetric changes in the lungs across this patient group.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

IPF, a chronic lung condition, is marked by tissue scarring that hinders the functioning of the lung.

Previously, Rein reported encouraging topline outcomes from Cohort 2 of the Phase Ib trial of LTI-03, showing a positive trend in seven out of eight biomarkers, with four biomarkers achieving statistical significance and five indicating dose-dependent effects.

The latest Phase II trial will assess the therapy’s safety, tolerability and its activity across various biomarkers in IPF patients.

It aims to measure the potential for tissue regeneration and the functioning of the lung.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Qureight’s role will include provision of end-to-end imaging core laboratory services, inclusive of data management, qualification of site, quality control and the application of AI for image analysis.

Its AI tools are set to measure changes in the vascular, airway and fibrotic compartments of the lung, providing an assessment of the therapy’s effect on pro-fibrotic activity and protection of alveolar epithelial cells.

The company’s technology is expected to streamline trial workflows and shorten the time needed for image interpretation.

Further details on the Phase II trial design will be disclosed by Rein shortly.

Rein Therapeutics CEO and president Brian Windsor said: “We are taking the evaluation of biomarkers a step further with the application of cutting-edge deep-learning imaging technology and detailed AI-based data analysis by collaborating with Qureight on this Phase II trial.

“These tools will be critical in gaining a deeper understanding of the potential therapeutic effect of LTI-03.”

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now